Pharmacokinetics and Initial Bolus Dosing of Furosemide in Children on ECMO
Extracorporeal membrane oxygenation (ECMO) is an established technology that provides life-saving mechanical support for critically ill children. In these children, fluid overload is commonly treated with furosemide; however, optimal dosing of furosemide is unknown in children supported with ECMO because ECMO may alter furosemide exposure. In this work, human blood-primed ex vivo experiments quantified red blood cell partitioning and extraction of furosemide by the ECMO circuit. Furosemide partitioned into red blood cells but was not extracted by ECMO circuits. These data then parameterized a pediatric physiologically based pharmacokinetic (PBPK) model of furosemide in children with and without ECMO. Next, plasma furosemide concentrations from 10 critically ill children supported by ECMO were used to evaluate PBPK model performance, with the optimized model achieving average fold error and absolute average fold error of 1.02 and 1.67, respectively. The optimized PBPK model also predicted that ECMO increases apparent volume of distribution by a median of > 30% in neonates and infants. Finally, population PBPK simulations with the optimized PBPK model provided initial bolus doses that most rapidly achieve steady-state plasma furosemide concentrations with and without ECMO. These calibrated initial bolus doses achieved steady-state plasma furosemide concentrations > 3 h faster than continuous infusions without an initial bolus dose, and this improvement was most pronounced in neonates and infants on ECMO. Overall, this work supports comparatively larger initial bolus doses for neonates and infants on ECMO, and provides calibrated initial bolus doses based on plasma exposure for critically ill children.
Authors
- Andrew Chevalier (ORCID: https://orcid.org/0000-0002-8573-6185)
- Aviva Whelan (ORCID: https://orcid.org/0000-0001-8968-3183)
- David J. Anderson (ORCID: https://orcid.org/0000-0002-5575-9167)
- Kevin Watt (ORCID: https://orcid.org/0000-0002-5975-5091)
- John Porter Hunt (ORCID: https://orcid.org/0000-0003-3503-8124)
- Autumn M. McKnite (ORCID: https://orcid.org/0000-0001-7985-2991)
- Ariel Tarrell (ORCID: https://orcid.org/0000-0002-5812-3332)
- Danielle J. Green (ORCID: https://orcid.org/0000-0001-6924-3797)
- Gideon A. Stitt (ORCID: https://orcid.org/0000-0001-5269-214X)
- Joseph E. Rower (ORCID: https://orcid.org/0000-0003-3629-7902)
- Carina E. Imburgia
Institutions
- University of Utah (US)
Publication Details
- Journal
- CPT Pharmacometrics & Systems Pharmacology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1002/psp4.70370
- Primary Topic
- Pharmaceutical studies and practices
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Foundation for Pharmaceutical Education
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute of Child Health and Human Development
- Eunice Kennedy Shriver National Institute of Child Health and Human Development